Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensive ...

Senate votes to avoid government shutdown as 10 Democrats vote with Republicans Myles Garrett’s Pitch to Russell Wilson on Joining the Browns Was Hilariously Simple Tesla may have no new car ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

0.51 points in the sham control group. The STRENGTH study found OAV101 IT stabilized motor function in patients who had discontinued Spinraza or Evrysdi over 52 weeks. Learn how to trade ...